Treatment Development of Triheptanoin (G1D)

Inclusion Criteria: * Diagnosis of glucose transporter type I deficiency (G1D) confirmed by genotyping or PET scan of the brain. * Stable on no dietary therapy other than Modified Atkins diet (i.e., on no dietary therapy for 1 month, including, but not limited to, medium chain triglyceride therapy). * Males and females 2 years 6 months to 35 years 11 months old, inclusive. Exclusion Criteria: * Subjects with a history of life-threatening seizure episodes, including but not limited to status epilepticus and cardiac arrest. * Subjects with evidence of independent, unrelated metabolic and/or genetic disease. * Subjects with a body mass index (BMI) greater than or equal to 30. * Subjects with a chronic gastrointestinal disorder, such as irritable bowel syndrome, Crohn's disease, or colitis, which could increase the subject's risk of developing diarrhea or stomach pain. * Subjects currently on dietary therapy (i.e., ketogenic diet, medium chain triglyceride-supplemented diets, Atkins diet, low glycemic index diet, and related diets). * Women who are pregnant or breast-feeding may not participate. * Women who plan to become pregnant during the course of the study, or who are unwilling to use birth control to prevent pregnancy (including abstinence) may not participate. * Females age 10 and over will be asked to provide a urine sample for a pregnancy test via dipstick. * Subjects will be asked to agree to abstinence or another form of birth control for the duration of the study. …